PRESS-RELEASE ·Filed Aug 10, 2026
Press release: earnings
Actionable Insight • Neutral
Monitor the Q2 2026 earnings release on August 13 for revenue, EPS, and pipeline updates, particularly regarding XPOVIO sales and myelofibrosis development. No pre-earnings trading signal from this announcement.
Latest settled — T+20d
KPTI ▼ -12.50% at T+20d
NEUTRAL call ✗ call lost -12.50% · α vs SPY -11.59% · entry $1.96 → $1.72
Latest observation: T+37 +42.58% FF3 residual α
T+1d
+7.14%
call +7.14% · α +7.46%
$2.10
settled 7w ago
T+5d
-7.65%
call -7.65% · α -7.61%
$1.81
settled 7w ago
T+20d
-12.50%
call -12.50% · α -11.59%
$1.72
settled 24d ago
T+60d
—
call — · α —
—
in 5w
Price Chart
Loading chart...
Executive Summary
Karyopharm Therapeutics announced it will report Q2 2026 financial results on August 13, 2026. This is a routine earnings date announcement with no financial data, guidance, or material business updates provided. The filing has no immediate trading implications.
Key Facts
- Karyopharm will report Q2 2026 financial results on August 13, 2026.
- A conference call is scheduled for 8:00 a.m. ET on the same day.
- No preliminary financial results or guidance were disclosed in this announcement.
Financial Impact
No financial data disclosed in this filing.
Risk Factors
- No financial data or guidance provided; stock may be volatile around the earnings date.
- Karyopharm is a commercial-stage biotech with ongoing cash burn; liquidity risk remains.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (12 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302845213 |
17 reports for KPTI
88% Hit rate best @ T+60▲ +71.57%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
Showing 10 of 17
US Market Status
Market Open — Closes in 2h 19m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access